Estrella Immunopharma, Inc. (ESLA) Fair Value 2026

ESLA · Biological Products, (No Diagnostic Substances) ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

3.3 /10

32 fundamental signals · 9 models active

Value Trap Risk

SAFE (12/100)

Quick Summary — As of 2026-07-15, Estrella Immunopharma, Inc. (ESLA) trades at $0.77, approximately 178% above CirclFi’s Bayesian DCF fair value of $0.28. QOC: 3.3/10. Value Trap Risk: 12/100 (SAFE). 9/13 models active.

Key Facts

Ticker
ESLA
Price
$0.77
Quality Score
3.3/10
Value Trap Risk
12/100
Models Active
9/13
Last Updated
Strength: First Chicago suggests +118.7% upside with 11% confidence
Risk: Below-average Quality Score of 3.3/10 signals weak fundamentals

Is Estrella Immunopharma, Inc. (ESLA) Undervalued or Overvalued in 2026?

According to CirclFi’s 9-model valuation engine, Estrella Immunopharma, Inc. (ESLA) appears undervalued as of : the median of 9 independent fair value estimates is $0.94, 21.6% above the current price of $0.77. Estimates range from $0.01 to $2.43. ESLA scores 3.3/10 on fundamental quality and 12/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Estrella Immunopharma, Inc. Stock in 2026? →

Valuation Matrix

9 Intrinsic Value Models vs. Current Price ($0.77)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
 $0.28 -64.0%
CUCE Ensemble
Low Conviction
 $0.58 -24.8%
First Chicago
Low Conviction
 $1.68 +118.7%
Dynamic NAV
Medium Conviction
 $0.12 -84.5%

Unlock the Full Matrix

Access 5 additional models including Markov DDM, ML-RIV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 9 Models →

Cancel anytime · No contracts · Instant access

What Is Estrella Immunopharma, Inc. (ESLA) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Estrella Immunopharma, Inc.'s intrinsic value is estimated at $0.97, suggesting a +25.9% average upside from the current price of $0.77. While 5 models see room for appreciation, model agreement is not unanimous as 4 models flag potential overvaluation. Model dispersion is worth noting: Markov DDM targets $2.43 (+216.0%), versus ML-RIV at $0.01 (-98.2%). This +314.1% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About ESLA?

9 of 13 models are currently active for ESLA. Of these, 5 models suggest upside while 4 models suggest overvaluation. The Bayesian DCF estimates ESLA's intrinsic value at $0.28, implying -64.0% downside from the current price. See which stocks rank higher →

How Does ESLA Rank in Biological Products, (No Diagnostic Substances)?

Among 134 Biological Products, (No Diagnostic Substances) stocks, ESLA ranks #125 by Quality of Company score. CirclFi's QOC score of 3.3/10 evaluates 32 fundamental signals. A score of 3.3 signals below-average fundamentals.

See all Most Undervalued Biological Products, (No Diagnostic Substances) Stocks →

Estrella Immunopharma, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is ESLA a Value Trap?

CirclFi's Value Trap algorithm assigns ESLA a score of 12/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

9 of 13 models are active for Estrella Immunopharma, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Estrella Immunopharma, Inc.'s fundamental quality profile registers 3.3/10. This concerning score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +314.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ESLA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ESLA's 9 active models, average confidence is 20%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Estrella Immunopharma, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biological Products, (No Diagnostic Substances) Stocks Should You Also Analyze?

8 related Biological Products, (No Diagnostic Substances) stocks with 13-model coverage

EXELExelixis, Inc.QOC 10.0HALOHalozyme Therapeutics, Inc.QOC 10.0NBIXNeurocrine Biosciences, Inc.QOC 10.0GILDGilead Sciences, Inc.QOC 9.7PLXProtalix BioTherapeutics, Inc. QOC 8.6BIIBBiogen Inc.QOC 8.4IMCRImmunocore Holdings plcQOC 7.9TECHBio-Techne CorpQOC 7.8

Read investment analysis: EXEL · HALO · NBIX · GILD · PLX

See all Biological Products, (No Diagnostic Substances) stocks ranked →

Frequently Asked Questions About Estrella Immunopharma, Inc.

What is Estrella Immunopharma, Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Estrella Immunopharma, Inc. (ESLA) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $0.28. The Quality of Company score is 3.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ESLA overvalued or undervalued right now?

At $0.77, 5 of 9 active models suggest ESLA may be undervalued, while 4 indicate potential overvaluation. The median of all 9 fair value estimates is $0.94, 21.6% above the current price of $0.77 — a consensus view that ESLA is undervalued. The assessment depends on which methodology best fits Estrella Immunopharma, Inc.'s business model in Biological Products, (No Diagnostic Substances).

What does a Quality of Company score of 3.3 mean for ESLA?

Estrella Immunopharma, Inc.'s QOC of 3.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on ESLA?

CirclFi analyzes ESLA with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 9 of 13 are active for this stock. Read the full methodology →

Is ESLA a value trap in 2026?

Estrella Immunopharma, Inc.'s Value Trap score is 12/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 9-model valuation engine, Estrella Immunopharma, Inc. (ESLA) has a median fair value of $0.94 — 21.6% above the current price of $0.77 — as of 2026-07-15.” Source: circlfi.com/stock/ESLA/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 9 mathematical frameworks give you clarity on ESLA.

Unlock All 9 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access